Please assess the completion status of the following clinical trial:

Trial Title: A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients eligible for the trial must comply with all of the following at randomization:~1. Age ≥ 14 years and \<65 years, male or non-pregnant women of childbearing-potential using an approved, effective method of contraception before, during and for at least 2 weeks after the completion of the active intervention with doxycycline or placebo~2. Able to give informed consent to participate in the trial (forms to be attached)~3. Resident in endemic area for five years or more~4. Body weight \>40 kg~5. Lymphedema of a limb Grade 1-6 measured on a 7-point scale. (Appendix 1 for explanation of the grading system (Dreyer G et al. 2002).~6. Ability to use established standardized methods of hygiene and effectively applying it prior to the initiation of the drug treatment~7. No evidence of severe or systemic comorbidities except for features of filarial disease~8. Normal laboratory profile (Appendix 3 investigations and the maximum or minimum limits in the case of hematological abnormalities - Site Specific)~9. Consent to storage of blood samples for study~Exclusion Criteria:~Patients are ineligible to participate in the trial, if they have any of the following:~1. No lymphedema or lymphedema stage 7~2. Age \< 14 years or \> 65 years~3. Body weight \< 40 kg~4. Pregnant or breastfeeding women~5. Women of childbearing potential not using an agreed method of contraception. (A pregnancy test will be conducted as part of the screening process to exclude pregnancy and repeated at 3 and 8 weeks. In addition, women of childbearing potential will be counseled against pregnancy during the treatment period)~6. Clinical or laboratory evidence of hepatic or renal dysfunction or CNS disease~7. Alcohol or drug abuse~8. History of adverse reactions to doxycycline or other tetracyclines~9. Patient has any situation or condition that may interfere with participation in the study as judged by the clinical investigator

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: ACTIVE_COMPARATOR): The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg).
- Placebo (Type: PLACEBO_COMPARATOR): The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete